{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:12:47Z","timestamp":1790007167105,"version":"4.0.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/crd.0b013e31823424be","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T11:04:11Z","timestamp":1328007851000},"page":"90-95","source":"Crossref","is-referenced-by-count":51,"title":["Mipomersen"],"prefix":"10.1097","volume":"20","author":[{"given":"Daniel N.","family":"Ricotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210203","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1161\/01.CIR.0000048067.86569.E1","article-title":"Primary prevention of cardiovascular disease: a call to action.","volume":"106","author":"Bonow","year":"2002","journal-title":"Circulation"},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association.","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev.nutr.20.1.169","article-title":"APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation.","volume":"20","author":"Davidson","year":"2000","journal-title":"Annu Rev Nutr"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0022-2275(20)39976-4","article-title":"Familial hypobetalipoproteinemia.","volume":"34","author":"Linton","year":"1993","journal-title":"J Lipid Res"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1194\/jlr.M200342-JLR200","article-title":"Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis.","volume":"44","author":"Schonfeld","year":"2003","journal-title":"J Lipid Res"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1194\/jlr.M300020-JLR200","article-title":"Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER.","volume":"44","author":"Liao","year":"2003","journal-title":"J Lipid Res"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0960-894X(03)00116-1","article-title":"Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents.","volume":"13","author":"Magnin","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1074\/jbc.275.11.7515","article-title":"A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion.","volume":"275","author":"Leung","year":"2000","journal-title":"J Biol Chem"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.","volume":"46","author":"Crooke","year":"2005","journal-title":"J Lipid Res"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(10)60364-9","article-title":"Antisense technology to lower LDL cholesterol.","volume":"375","author":"Neely","year":"2010","journal-title":"Lancet"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11883-009-0078-7","article-title":"Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.","volume":"12","author":"Thomas","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.","volume":"55","author":"Akdim","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R22-6-20210203","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"R23-6-20210203","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms.","volume":"1","author":"Dias","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1440-1681.2009.05337.x","article-title":"Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.","volume":"37","author":"Pocathikorn","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R25-6-20210203","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.","volume":"111","author":"Rader","year":"2003","journal-title":"J Clin Invest"},{"key":"R26-6-20210203","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.","volume":"90","author":"Gagne","year":"2002","journal-title":"Am J Cardiol"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood.V98.4.995","article-title":"The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5-nucleotidase.","volume":"98","author":"Koziolkiewicz","year":"2001","journal-title":"Blood"},{"key":"R28-6-20210203","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V90.1.331.331_331_339","article-title":"Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides.","volume":"90","author":"Vaerman","year":"1997","journal-title":"Blood"},{"key":"R29-6-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1566524043360375","article-title":"Antisense strategies.","volume":"4","author":"Crooke","year":"2004","journal-title":"Curr Mol Med"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","article-title":"Cross-species comparison of in vivo PKPD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.","volume":"77","author":"Yu","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"R31-6-20210203","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R32-6-20210203","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjcard.2005.11.039","article-title":"Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"R33-6-20210203","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis.","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"R35-6-20210203","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/clinchem\/44.11.2301","article-title":"Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies.","volume":"44","author":"Craig","year":"1998","journal-title":"Clin Chem"},{"key":"R36-6-20210203","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/01.CIR.80.5.1313","article-title":"HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.","volume":"80","author":"Kostner","year":"1989","journal-title":"Circulation"},{"key":"R37-6-20210203","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"key":"R39-6-20210203","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.","volume":"51","author":"Visser","year":"2010","journal-title":"J Lipid Res"},{"key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jacl.2011.08.007","article-title":"Antisense therapy and emerging applications for the management of dyslipidemia.","volume":"5","author":"Toth","year":"2011","journal-title":"J Clin Lipidol"},{"key":"R41-6-20210203","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ejim.2011.06.015","article-title":"Antisense therapy in the treatment of hypercholesterolemia.","volume":"22","author":"Lippi","year":"2011","journal-title":"Eur J Intern Med"},{"key":"R42-6-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/13543784.2011.547471","article-title":"Mipomersen, an antisense apolipoprotein B synthesis inhibitor.","volume":"20","author":"Bell","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"R43-6-20210203","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1517\/14656566.2010.512006","article-title":"Mipomersen as a potential adjunctive therapy for hypercholesterolemia.","volume":"11","author":"Patel","year":"2010","journal-title":"Expert Opin Pharmacother"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0b013e31823424be","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:54:27Z","timestamp":1620950067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201203000-00006"}},"subtitle":["A Safe and Effective Antisense Therapy Adjunct to Statins in Patients With Hypercholesterolemia"],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e31823424be","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}